Roux-en-Y胃旁路术诱导肝脏转录组特征和血浆代谢物变化,提示胆固醇稳态改善
研究对26例肥胖非糖尿病患者在Roux-en-Y胃旁路术(RYGB)前及术后1年进行肝脏转录组分析和血浆胆固醇代谢物及胆汁酸定量检测。RYGB改善了全身胆固醇代谢,上调胆汁酸代谢相关基因模块,提示胆道胆固醇排泄增加及替代途径胆汁酸合成增强。RYGB改变了肝脏转录组特征,可能改善肝脏胆固醇稳态,全身代谢物变化印证了其对肝脏和全身胆固醇稳态的益处。
要点
- RYGB术后1年肝脏炎症相关基因模块下调,胆汁酸代谢相关基因模块上调。
- RYGB术后胆道胆固醇排泄增加,与替代途径而非经典途径胆汁酸合成增强相关。
- RYGB降低血浆胆固醇合成标志物,与术后肝病状态改善相关。
核心结论
- RYGB对炎症和胆固醇代谢具有特定调控作用,改变肝脏转录组特征,可能改善肝脏胆固醇稳态。
- 这些基因调控效应反映在术后胆固醇相关代谢物的全身变化中,印证了RYGB对肝脏和全身胆固醇稳态的益处。
研究设计与样本
- 研究纳入26例肥胖但非糖尿病患者,在RYGB术前和术后1年进行肝脏转录组分析。
- 同时定量检测血浆胆固醇代谢物和胆汁酸的变化。
主要发现
- RYGB改善了全身胆固醇代谢,并升高血浆总胆汁酸和初级胆汁酸水平。
- 转录组分析显示RYGB后肝脏特定改变:炎症相关基因模块下调,三个模块上调,其中一个与胆汁酸代谢相关。
- 胆固醇稳态相关肝脏基因分析提示RYGB后胆道胆固醇排泄增加,与替代途径而非经典途径胆汁酸合成增强相关。
- 胆固醇摄取和细胞内转运相关基因表达改变,提示肝脏游离胆固醇处理改善。
- RYGB降低血浆胆固醇合成标志物,与术后肝病状态改善相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Roux-en-Y gastric bypass (RYGB), the most effective surgical procedure for weight loss, decreases obesity and ameliorates comorbidities, such as non-alcoholic fatty liver (NAFLD) and cardiovascular (CVD) diseases. Cholesterol is a major CVD risk factor and modulator of NAFLD development, and the liver tightly controls its metabolism. How RYGB surgery modulates systemic and hepatic cholesterol metabolism is still unclear. METHODS: We studied the hepatic transcriptome of 26 patients with obesity but not diabetes before and 1 year after undergoing RYGB. In parallel, we measured quantitative changes in plasma cholesterol metabolites and bile acids (BAs). RESULTS: RYGB surgery improved systemic cholesterol metabolism and increased plasma total and primary BA levels. Transcriptomic analysis revealed specific alterations in the liver after RYGB, with the downregulation of a module of genes implicated in inflammation and the upregulation of three modules, one associated with BA metabolism. A dedicated analysis of hepatic genes related to cholesterol homeostasis pointed towards increased biliary cholesterol elimination after RYGB, associated with enhancement of the alternate, but not the classical, BA synthesis pathway. In parallel, alterations in the expression of genes involved in cholesterol uptake and intracellular trafficking indicate improved hepatic free cholesterol handling. Finally, RYGB decreased plasma markers of cholesterol synthesis, which correlated with an improvement in liver disease status after surgery. CONCLUSIONS: Our results identify specific regulatory effects of RYGB on inflammation and cholesterol metabolism. RYGB alters the hepatic transcriptome signature, likely improving liver cholesterol homeostasis. These gene regulatory effects are reflected by systemic post-surgery changes of cholesterol-related metabolites, corroborating the beneficial effects of RYGB on both hepatic and systemic cholesterol homeostasis. IMPACT AND IMPLICATIONS: Roux-en-Y gastric bypass (RYGB) is a widely used bariatric surgery procedure with proven efficacy in body weight management, combatting cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). RYGB exerts many beneficial metabolic effects, by lowering plasma cholesterol and improving atherogenic dyslipidemia. Using a cohort of patients undergoing RYGB, studied before and 1 year after surgery, we analyzed how RYGB modulates hepatic and systemic cholesterol and bile acid metabolism. The results of our study provide important insights on the regulation of cholesterol homeostasis after RYGB and open avenues that could guide future monitoring and treatment strategies targeting CVD and NAFLD in obesity.
引用
- Lalloyer F, Mogilenko DA, Verrijken A, et al. Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis. J Hepatol. 2023. PMID: 37230231. doi:10.1016/j.jhep.2023.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。